Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand and the willingness to sign a written informed consent document.~2. Histologically confirmed Stage III-IV (T1, T2, T3) (N0-N2) squamous cell carcinoma of the oropharynx staged according to AJCC guidelines.~3. The subject must be considered surgically resectable via a transoral approach at the time of presentation.~4. Age \>18 years~5. Life expectancy \>/= 5 years~6. ECOG performance status \<2~7. Subject must have measurable disease, at least one lesion accurately measured in at least one dimension as \>10 mm with CT scan.~8. Hematologic Absolute neutrophil count \> 1,000/mm3, Hemoglobin \> 8.0 g/dl Platelet count \> 100,000/mm3 Leukocytes \>3,000/mcL~9. Hepatic Total Bilirubin ≤ ULN; AST and ALT and Alkaline Phosphatase within the eligible range~10. Renal - creatinine within normal institutional limits or \>60 mL/min/1.73 m2 creatinine \> institutional normal~11. Women of childbearing potential with negative pregnancy test.~12. Men and women of childbearing age willing to use effective contraception~Exclusion Criteria:~1. N3 nodal disease according to AJCC guidelines~2. Retropharyngeal nodal involvement~3. Trismus~4. Second primary head and neck tumor unless it is/was a basal or squamous cell skin cancer~5. Prior surgery, chemotherapy, biologic or radiotherapy for a head or neck malignancy~6. Concurrent investigational agent or intervention (within 90 days of screening visit)~7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxol, cisplatin, 5- fluorouracil, or carboplatin.~8. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80~9. Breastfeeding women~10. Pre-existing peripheral neuropathy grade \> 3~11. Evidence of distant metastatic disease~12. Unknown primary site~13. Prior or concurrent malignancies (excluding adequately treated basal or squamous cell skin cancer, in situ cervical cancer, stage I or II cancer from which the subject has been in complete remission for at least 12 months (excluding head and neck), any cancer from which the subject has been cancer free for 5 years)~14. History of allergies to any of the pre-medications.~15. Investigator consideration based upon screening interview and/or procedures~16. Evidence of bone invasion/destruction~17. Uncontrolled intercurrent illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~18. Pregnant women~19. History of HIV, hepatitis B, hepatitis C, or delta antigen~20. Known allergy to India Ink or methylene blue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- radiation and weekly carboplatin (Type: ACTIVE_COMPARATOR): None
- conservation surgery (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues